The earnings miss may pressure PVLA shares near-term, but the strong cash runway and upcoming NDA submission provide a catalyst. Watch for pre-NDA meeting outcomes and pipeline milestones in 2H 2026.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $113.26entry
- T+1 · 6mo ago +7.09%α +6.26% · $121.29
- T+5 · 6mo ago +6.45%α +4.95% · $120.57
- T+20 · 6mo ago +1.91%α −1.23% · $115.42
- T+60 · 4mo ago +24.30%α +20.46% · $140.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics reported Q1 2026 EPS of -$1.20, missing consensus of -$0.93 by 29%, as R&D and G&A expenses rose sharply. Despite the miss, the company highlighted strong cash of $261.9M and reiterated NDA submission for QTORIN rapamycin in microcystic LMs in 2H 2026, with potential approval and launch in 1H 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.20 missed consensus of -$0.93 (29% miss)
- Net loss of $15.8M vs $8.2M in Q1 2025, driven by higher R&D and G&A costs
- Cash, cash equivalents and short-term investments of $261.9M as of March 31, 2026
- NDA submission for QTORIN rapamycin in microcystic LMs on track for 2H 2026
- Phase 3 SELVA study met all primary and secondary endpoints; pre-NDA meeting granted
Financial Impact
EPS miss of $0.27 per share
Risk Factors
- EPS miss may lead to negative sentiment and near-term selling
- Clinical and regulatory risks ahead of NDA submission and approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210605 |
| Document: pvla-20260507.htm | 0001193125-26-210605 |
| Document: pvla-ex99_2.htm | 0001193125-26-210605 |
| Document: 0001193125-26-210605-index-headers.html | 0001193125-26-210605 |
| Document: 0001193125-26-210605-index.html | 0001193125-26-210605 |
| Document: 0001193125-26-210605.txt | 0001193125-26-210605 |
| 8-K Data (Synthetic) | 0001193125-26-210605 |
Track record
36 reports on PVLA
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers